Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MLAB 
Mesa Laboratories Inc (MLAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/27/2025: MLAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50.62% | Avg. Invested days 24 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 638.39M USD | Price to earnings Ratio - | 1Y Target Price 150 |
Price to earnings Ratio - | 1Y Target Price 150 | ||
Volume (30-day avg) 32684 | Beta 0.82 | 52 Weeks Range 83.37 - 154.94 | Updated Date 04/1/2025 |
52 Weeks Range 83.37 - 154.94 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 0.54% | Basic EPS (TTM) -46.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -104.92% | Operating Margin (TTM) 9.2% |
Management Effectiveness
Return on Assets (TTM) 2.18% | Return on Equity (TTM) -89.38% |
Valuation
Trailing PE - | Forward PE 35.21 | Enterprise Value 819050486 | Price to Sales(TTM) 2.69 |
Enterprise Value 819050486 | Price to Sales(TTM) 2.69 | ||
Enterprise Value to Revenue 3.45 | Enterprise Value to EBITDA 305.65 | Shares Outstanding 5433610 | Shares Floating 5291246 |
Shares Outstanding 5433610 | Shares Floating 5291246 | ||
Percent Insiders 5.75 | Percent Institutions 95.92 |
Analyst Ratings
Rating 3.5 | Target Price 133.33 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Mesa Laboratories Inc
Company Overview
History and Background
Mesa Laboratories, Inc. was founded in 1982. It designs, manufactures, and markets quality control instruments and consumable products used in healthcare, pharmaceutical, medical device, industrial, and food processing applications.
Core Business Areas
- Sterilization and Disinfection Control: Offers biological indicators, chemical indicators, and related equipment for sterilization and disinfection monitoring.
- Biopharmaceutical Development: Provides products and services for biopharmaceutical manufacturing, including process development and analytical testing.
- Instruments: Designs and manufactures precision measurement instruments, including data loggers and calibration equipment.
Leadership and Structure
The leadership team is composed of a Chief Executive Officer, Chief Financial Officer, and various Vice Presidents overseeing different business segments. The company has a typical corporate structure with departments for finance, operations, sales, marketing, and research and development.
Top Products and Market Share
Key Offerings
- Biological Indicators (BIs): BIs are used to monitor sterilization processes. Mesa Labs is a leading provider of BIs. Market share data varies but the are a significant player in this market. Competitors include STERIS, 3M, and Cantel Medical (now part of STERIS).
- Data Loggers: Used for environmental monitoring and validation. Mesa Labs provides specific data loggers for many specific applications, including environmental. Competitors include Vaisala and Dickson.
Market Dynamics
Industry Overview
The market is driven by stringent regulations in healthcare, pharmaceutical, and food industries, which require rigorous quality control and validation processes. The market is seeing growth from increasing global healthcare spending and rising awareness of infection control.
Positioning
Mesa Labs is positioned as a provider of high-quality, reliable products and services in quality control and validation. Its competitive advantages include its established reputation, technical expertise, and broad product portfolio.
Total Addressable Market (TAM)
The total addressable market is in the billions of dollars, with increasing demand for sterilization and disinfection control solutions. Mesa Labs is well-positioned to capture a significant share of this market due to its specialized expertise and regulatory compliance focus.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- High-quality products
- Regulatory expertise
- Diverse product portfolio
- Established customer base
Weaknesses
- Reliance on specific industries
- Limited global presence compared to larger competitors
- Potential vulnerability to technological advancements
Opportunities
- Expanding into emerging markets
- Developing new products and services
- Acquiring complementary businesses
- Increasing demand for sterilization products
Threats
- Increased competition
- Changing regulations
- Economic downturns
- Technological disruptions
Competitors and Market Share
Key Competitors
- STERIS (STE)
- 3M (MMM)
- Danaher Corporation (DHR)
Competitive Landscape
Mesa Labs benefits from its specialized expertise and regulatory focus, allowing it to compete effectively in niche markets. However, larger competitors have greater resources and broader product portfolios.
Major Acquisitions
Gyros Protein Technologies Holding AB
- Year: 2022
- Acquisition Price (USD millions): 247
- Strategic Rationale: The acquisition of Gyros Protein Technologies expanded Mesa's biopharmaceutical development capabilities.
Growth Trajectory and Initiatives
Historical Growth: Mesa Labs has shown consistent growth, driven by both organic expansion and strategic acquisitions.
Future Projections: Future growth is projected to be driven by increasing demand for quality control and validation solutions in healthcare and biopharmaceutical industries. Analyst estimates suggest continued revenue and earnings growth.
Recent Initiatives: Recent initiatives include acquisitions to expand product offerings, investments in research and development, and efforts to increase market penetration in key regions.
Summary
Mesa Laboratories is a strong player in the niche market of quality control and validation. Its focus on regulatory compliance and specialized expertise positions it well for continued growth. The company should watch out for increasing competition and technological disruptions. Strategic acquisitions and expansion into emerging markets offer significant opportunities.
Similar Companies
- STE
- DHR
- MMM
- WAT
- ILMN
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mesa Laboratories Inc
Exchange NASDAQ | Headquaters Lakewood, CO, United States | ||
IPO Launch date 1995-01-25 | CEO, President & Director Mr. Gary M. Owens | ||
Sector Technology | Industry Scientific & Technical Instruments | Full time employees 736 | Website https://www.mesalabs.com |
Full time employees 736 | Website https://www.mesalabs.com | ||
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.